Price T Rowe Associates Inc Repligen Corp Transaction History

Price T Rowe Associates Inc

$935 Billion
Q3 2025

A detailed history of Price T Rowe Associates Inc transactions in Repligen Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,507,378 shares of RGEN stock, worth $534 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

3,507,378

Previous 6,603,954 46.89%

Holding current value

$534 Million

Previous $821 Million 42.92%

% of portfolio

0.05%

Previous 0.09%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$111.43 - $134.0 $345 Million - $415 Million	-3,096,576 Reduced 46.89%	3,507,378 $469 Million
Q2 2025 Aug 14, 2025	SELL	$108.89 - $145.23 $105 Million - $140 Million	-962,139 Reduced 12.72%	6,603,954 $821 Million
Q1 2025 May 14, 2025	BUY	$127.24 - $174.24 $54.7 Million - $74.9 Million	430,039 Added 6.03%	7,566,093 $963 Million
Q4 2024 Feb 14, 2025	BUY	$123.41 - $160.92 $91.8 Million - $120 Million	743,815 Added 11.64%	7,136,054 $1.03 Billion
Q3 2024 Nov 14, 2024	BUY	$119.79 - $167.35 $214 Million - $299 Million	1,783,806 Added 38.71%	6,392,239 $951 Million

Q2 2024 Aug 14, 2024	BUY	$120.0 - $182.95 $125 Million - $190 Million	1,040,117 Added 29.15%	4,608,433 $581 Million
Q1 2024 May 15, 2024	SELL	$170.78 - $208.42 $75.5 Million - $92.1 Million	-441,939 Reduced 11.02%	3,568,316 $656 Million
Q4 2023 Feb 14, 2024	BUY	$114.17 - $185.35 $23.8 Million - $38.6 Million	208,413 Added 5.48%	4,010,255 $721 Million
Q3 2023 Nov 14, 2023	BUY	$138.78 - $176.51 $11.8 Million - $15 Million	85,077 Added 2.29%	3,801,842 $605 Million
Q2 2023 Aug 14, 2023	SELL	$138.42 - $180.31 $6.23 Million - $8.12 Million	-45,033 Reduced 1.2%	3,716,765 $526 Million
Q1 2023 May 15, 2023	SELL	$154.26 - $198.1 $202 Million - $259 Million	-1,308,859 Reduced 25.81%	3,761,798 $633 Million
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $229 Million - $311 Million	1,411,078 Added 38.56%	5,070,657 $859 Million
Q3 2022 Nov 14, 2022	SELL	$160.42 - $256.21 $300 Million - $480 Million	-1,871,942 Reduced 33.84%	3,659,579 $685 Million
Q2 2022 Aug 15, 2022	BUY	$140.68 - $188.02 $247 Million - $330 Million	1,755,417 Added 46.49%	5,531,521 $898 Million
Q1 2022 May 16, 2022	BUY	$161.19 - $257.96 $118 Million - $189 Million	733,449 Added 24.11%	3,776,104 $710 Million
Q4 2021 Feb 14, 2022	BUY	$247.59 - $304.47 $183 Million - $224 Million	737,206 Added 31.98%	3,042,655 $806 Million
Q3 2021 Nov 15, 2021	BUY	$194.77 - $324.21 $107 Million - $178 Million	550,303 Added 31.35%	2,305,449 $666 Million
Q2 2021 Aug 16, 2021	BUY	$165.87 - $220.95 $72.3 Million - $96.3 Million	435,972 Added 33.05%	1,755,146 $350 Million
Q1 2021 May 17, 2021	BUY	$180.37 - $226.26 $23.6 Million - $29.6 Million	130,709 Added 11.0%	1,319,174 $256 Million
Q4 2020 Feb 16, 2021	BUY	$148.08 - $206.57 $176 Million - $246 Million	1,188,465 New	1,188,465 $228 Million

Others Institutions Holding RGEN

# of Institutions

521

Shares Held

58.7M

Call Options Held

321K

Put Options Held

667K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.46B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Repligen Corp Transaction History